Clinical trial
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI…
NCT00226655 · Celtic Pharma Development Services, Industry · Completed
Key facts
| NCT number | NCT00226655 |
|---|---|
| Title | An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies |
| Official title | An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies |
| Lead sponsor | Celtic Pharma Development Services, Industry |
| Collaborators | Neurobiological Technologies Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain Edema, Brain Tumor |
| Intervention type | Drug |
| Interventions | hCRF [XERECEPT (corticorelin acetate injection)] |
| Enrollment | 112 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Sep 27, 2005 |
| Last update posted | Aug 31, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: